Home LiteratureArticle Details

PMID: 533575 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial

Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

British journal of clinical pharmacology ·Vol. 8 ·No. 6 ·1979-12-00 ·Pages 529-37

Danhof M, Breimer DD

Abstract

暂无摘要

MeSH Terms

Administration, Oral Antipyrine/administration & dosage,metabolism,urine Biotransformation Half-Life Humans Male Time Factors

Chemicals

Antipyrine

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Danhof M

Breimer D D

References (20)

20 references, click to expand

The fate of antipyrine in man.
J Pharmacol Exp Ther. 1950 Jan;98(1):97-104 PMID: 15403625
Genetic and environmental factors affecting drug disposition in man.
Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):659-79 PMID: 334437
Use of saliva in therapeutic drug monitoring.
Clin Chem. 1977 Feb;23(2 PT. 1):157-64 PMID: 318941
Polymorphic hydroxylation of Debrisoquine in man.
Lancet. 1977 Sep 17;2(8038):584-6 PMID: 71400
Factors influencing antipyrine elimination.
Br J Clin Pharmacol. 1977 Jun;4(3):261-5 PMID: 332216
[On the metabolism of antipyrine (phenazone) in man (author's transl)].
Arzneimittelforschung. 1978;28(2):315-9 PMID: 580401
Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.
Pharmacology. 1979;18(4):210-23 PMID: 461498
Metabolic disposition of antipyrine in patients with lung cancer.
Cancer Res. 1977 Nov;37(11):3881-6 PMID: 908027
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.
Eur J Clin Pharmacol. 1976 Feb 6;9(4):327-32 PMID: 971716
Assessment of antipyrine kinetics by measurement in saliva.
Br J Clin Pharmacol. 1976 Apr;3(2):321-5 PMID: 973966
Metabolism of drugs. LIX. A new metabolite of antipyrine.
Biochem Pharmacol. 1968 Aug;17(8):1511-6 PMID: 5672814
Interindividual differences in drug oxidation: clinical importance.
Drug Metab Dispos. 1973 Jan-Feb;1(1):469-82 PMID: 4149420
Genetic and environmental factors affecting drug response in man.
Fed Proc. 1972 Jul-Aug;31(4):1253-69 PMID: 4114107
Norphenazone, a new metabolite of phenazone in human urine.
J Pharm Pharmacol. 1973 Jan;25(1):83-4 PMID: 4146209
The effect of spironolactone on antipyrine metabolism in man.
Pharmacology. 1973;10(6):338-44 PMID: 4593769
Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man.
Biochem Pharmacol. 1974 Jan 15;23(2):197-201 PMID: 4813341
Antipyrine: radioimmunoassay in plasma and saliva following administration of a high dose and a low dose.
Clin Pharmacol Ther. 1976 Aug;20(2):219-26 PMID: 947654
Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.
Clin Pharmacol Ther. 1975 Sep;18(3):259-72 PMID: 1164816
Elimination of antipyrine from saliva as a measure of metabolism in man.
Clin Pharmacol Ther. 1975 Sep;18(3):249-58 PMID: 1164815
Metabolism of drugs. LXX. Further study on antipyrine metabolism.
Chem Pharm Bull (Tokyo). 1971 Jan;19(1):41-5 PMID: 5544367

Article Info

Journal

British journal of clinical pharmacology

Abbr.

Br J Clin Pharmacol

ISSN

0306-5251

DOI

10.1111/j.1365-2125.1979.tb01040.x

Published

1979-12-00

Pages

529-37

Language

English

Region

England

NLM ID

7503323

PMCID

PMC1429894

Subset

External Links

PubMed source DOI: 10.1111/j.1365-2125.1979.tb01040.x PMC Full Text View journal details

Analysis Services

Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Contact

WeChat Official Account